Accession Number: | 0001127602-21-021352 |
Date: | 2021-07-01 |
Issuer: | BIOGEN INC. (BIIB) |
Original Submission Date: |
DENNER ALEXANDER J
BIOGEN INC.
225 BINNEY ST.
CAMBRIDGE, MA 02142
Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
---|---|---|---|---|---|---|---|---|---|
COMMON STOCK | 2021-07-01 | A | 775 | a | $0.00 | 13,729 | direct | ||
COMMON STOCK | 2021-07-01 | 0 | $0.00 | 643,000 | indirect | f2 |
Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
---|
ID | footnote |
---|---|
f1 | dr. denner disclaims beneficial ownership of the shares being reported on this form 4 except to the extent of his pecuniary interest therein. |
f2 | sarissa capital management lp ("sarissa capital") is the investment advisor to certain investment funds, including the funds that directly beneficially own the securities reported herein (the "sarissa funds"). alexander denner is the chief investment officer of sarissa capital and controls the ultimate general partner of the sarissa funds. by virtue of the foregoing, dr. denner may be deemed to indirectly beneficially own (as that term is defined in rule 13d-3 of the securities exchange act of 1934, as amended) the shares that the sarissa funds directly beneficially own. |